Merus Labs
Toronto
About Merus Labs
The Merus corporate growth strategy is driven by a product acquisition plan which employs an opportunistic approach to source product acquisition candidates. This approach allows Merus to source pharmaceutical products across broad therapeutic classes which provides access to acquisition targets not available to other players and creates a diversified strategy. Although Merus has a broad therapeutic focus, opportunities will be pursued if the application of a dedicated small scale sales force can deliver incremental product sales growth. The geographic focus will be the United States and Canada
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $74.3M
- Funding stage: M&A
- Last round: Post-IPO Equity (Apr 2015)
- Ticker: nasdaq:MSLI
- Website: meruslabs.com
- Phone: +1 416 593 3725
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/merus-labs-2061328 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.